Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Chitinase 3 like 1 contributes to the development of pulmonary vascular remodeling in pulmonary hypertension
Xiuna Sun, … , James R. Klinger, Yang Zhou
Xiuna Sun, … , James R. Klinger, Yang Zhou
Published August 11, 2022
Citation Information: JCI Insight. 2022;7(18):e159578. https://doi.org/10.1172/jci.insight.159578.
View: Text | PDF
Research Article Cardiology Pulmonology

Chitinase 3 like 1 contributes to the development of pulmonary vascular remodeling in pulmonary hypertension

  • Text
  • PDF
Abstract

Chitinase 3 like 1 (CHI3L1) is the prototypic chitinase-like protein mediating inflammation, cell proliferation, and tissue remodeling. Limited data suggest CHI3L1 is elevated in human pulmonary arterial hypertension (PAH) and is associated with disease severity. Despite its importance as a regulator of injury/repair responses, the relationship between CHI3L1 and pulmonary vascular remodeling is not well understood. We hypothesize that CHI3L1 and its signaling pathways contribute to the vascular remodeling responses that occur in pulmonary hypertension (PH). We examined the relationship of plasma CHI3L1 levels and severity of PH in patients with various forms of PH, including group 1 PAH and group 3 PH, and found that circulating levels of serum CHI3L1 were associated with worse hemodynamics and correlated directly with mean pulmonary artery pressure and pulmonary vascular resistance. We also used transgenic mice with constitutive knockout and inducible overexpression of CHI3L1 to examine its role in hypoxia-, monocrotaline-, and bleomycin-induced models of pulmonary vascular disease. In all 3 mouse models of pulmonary vascular disease, pulmonary hypertensive responses were mitigated in CHI3L1-null mice and accentuated in transgenic mice that overexpress CHI3L1. Finally, CHI3L1 alone was sufficient to induce pulmonary arterial smooth muscle cell proliferation, inhibit pulmonary vascular endothelial cell apoptosis, induce the loss of endothelial barrier function, and induce endothelial-mesenchymal transition. These findings demonstrate that CHI3L1 and its receptors play an integral role in pulmonary vascular disease pathobiology and may offer a target for the treatment of PAH and PH associated with fibrotic lung disease.

Authors

Xiuna Sun, Erika Nakajima, Carmelissa Norbrun, Parand Sorkhdini, Alina Xiaoyu Yang, Dongqin Yang, Corey E. Ventetuolo, Julie Braza, Alexander Vang, Jason Aliotta, Debasree Banerjee, Mandy Pereira, Grayson Baird, Qing Lu, Elizabeth O. Harrington, Sharon Rounds, Chun Geun Lee, Hongwei Yao, Gaurav Choudhary, James R. Klinger, Yang Zhou

×

Figure 7

CHI3L1 synergizes with TGF-β or hypoxia to promote endothelial permeability and endo-MT.

Options: View larger image (or click on image) Download as PowerPoint
CHI3L1 synergizes with TGF-β or hypoxia to promote endothelial permeabil...
BPAECs were treated with CHI3L1 (500 ng/mL), TGF-β (10 ng/mL), or both for 48 hours. Transcript levels of (A) VE-cadherin and (B) α-SMA were measured in RNA extracts using RT-PCR. Protein levels of (C) VE-cadherin and (D) α-SMA were quantitated by Western blot analysis. (E) Immunostaining of VE-cadherin in cells treated with various conditions. (F) Endothelial permeability was measured by HRP leakage. Data are expressed as ΔOD470 for permeation of HRP across Transwell filters. In a separate experiment, BPAECs were treated with CHI3L1 (500 ng/mL), exposed to hypoxia (1% oxygen), or both. Transcript levels of (G) VE-cadherin and (H) α-SMA were measured in RNA extracts using RT-PCR. Protein levels of (I) VE-cadherin and (J) α-SMA were quantitated by Western blot analysis. (K) Immunostaining of VE-cadherin in cells treated with various conditions. (L) Endothelial permeability was measured by HRP leakage. Values are mean ± SEM with a minimum of 3 wells in each group. Each experiment was undertaken at least 3 times. Groups were compared by ANOVA with Bonferroni’s post test; follow-up comparisons between groups were conducted using a 2-tailed Student’s t test. ****P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05 compared with controls.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts